噻托溴铵和舒利迭联用对中重度COPD患者肺功能的影响

目的:观察舒利迭联合噻托溴铵和单用舒利迭治疗中重度慢性阻塞性肺疾病(COPD)肺功能的效果。方法:将91例中重度COPD患者随机分为观察组49例和对照组42例。对照组单用舒利迭(沙美特罗50μg,氟替卡松500μg),早晚各1次吸入;观察组在此基础上联合使用噻托溴铵胶囊(18μg),每天上午吸入1次,疗程均为6个月,对两组患者治疗前以及治疗3个月时肺功能指标、呼吸困难评分、随访期内急性发作次数、医疗费用等情况进行评价比较。结果:治疗3个月时观察组肺功能指标均优于对照组,在治疗阶段观察组呼吸困难评分明显低于对照组,观察组的随访期内急性发作次数明显低于对照组患者,但观察组住院费用高于对照组,差异均具有统计学意义(P均<0.05)。结论:舒利迭联合噻托溴铵治疗中重度COPD较单用舒利迭对患者肺功能和生活质量的改善作用更明显。

Effects of salmeterol combined with tiotropium bromide on pulmonary function of patients with chronic obstructive pulmonary disease

Objective:To evaluate the effects of salmeterol combined with tiotropium bromide on the pulmonary function of patients with moderate to severe chronic obstructive pulmonary disease(COPD).Methods:A total of 91 cases with moderate to severe COPD were selected and randomly divided into observation group and the control group.The observation group was given salmeterol(50 μg of salmeterol and fluticasone propionate 500 μg) inhalation twice daily and combined with tiotropium bromide 18 μg once daily;the control group was given salmeterol inhalation twice daily,which all lasted for 6 months.The pulmonary function,dyspnea score,the times of acute exacerbation,medical costs in the two groups before and after the treatment were compared.Results:After treatment,the lung function indicators of observation group were significant improved,dyspnea score and the times of acute exacerbation were significantly lower but the medical cost was much higher(P<0.05).Conclusions:Effects of salmeterol combined with tiotropium bromide on pulmonary function and quality of life of patients with COPD were better than single application of salmeterol.